155 related articles for article (PubMed ID: 34786492)
1. Gaining insights into relevance across cancers based on mutation features of TP53 gene.
Mei Y; Liang D; Wang T; Yu D
Biochem Biophys Rep; 2021 Dec; 28():101165. PubMed ID: 34786492
[TBL] [Abstract][Full Text] [Related]
2. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
[TBL] [Abstract][Full Text] [Related]
3. Patterns and processes of somatic mutations in nine major cancers.
Jia P; Pao W; Zhao Z
BMC Med Genomics; 2014 Feb; 7():11. PubMed ID: 24552141
[TBL] [Abstract][Full Text] [Related]
4. Somatic genome alterations in relation to age in lung adenocarcinoma.
Meucci S; Keilholz U; Heim D; Klauschen F; Cacciatore S
Int J Cancer; 2019 Oct; 145(8):2091-2099. PubMed ID: 30859574
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis reveals distinct mutational signature and its mechanistic insights of alcohol consumption in human cancers.
Wei R; Li P; He F; Wei G; Zhou Z; Su Z; Ni T
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32480415
[TBL] [Abstract][Full Text] [Related]
6. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
7. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
Li VD; Li KH; Li JT
J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
[TBL] [Abstract][Full Text] [Related]
9. Genomic Analysis Revealed New Oncogenic Signatures in
Kancherla V; Abdullazade S; Matter MS; Lanzafame M; Quagliata L; Roma G; Hoshida Y; Terracciano LM; Ng CKY; Piscuoglio S
Front Genet; 2018; 9():2. PubMed ID: 29456550
[TBL] [Abstract][Full Text] [Related]
10. Correlation-based and feature-driven mutation signature analyses to identify genetic features associated with DNA mutagenic processes in cancer genomes.
Jeong HY; Yoo J; Kim H; Kim TM
Genomics Inform; 2021 Dec; 19(4):e40. PubMed ID: 35172473
[TBL] [Abstract][Full Text] [Related]
11. Expression signatures of TP53 mutations in serous ovarian cancers.
Bernardini MQ; Baba T; Lee PS; Barnett JC; Sfakianos GP; Secord AA; Murphy SK; Iversen E; Marks JR; Berchuck A
BMC Cancer; 2010 May; 10():237. PubMed ID: 20504346
[TBL] [Abstract][Full Text] [Related]
12. Correlate the
Lyu H; Li M; Jiang Z; Liu Z; Wang X
Comput Struct Biotechnol J; 2019; 17():1020-1030. PubMed ID: 31428295
[TBL] [Abstract][Full Text] [Related]
13. Significant Prognostic Features and Patterns of Somatic
Zhang W; Edwards A; Flemington EK; Zhang K
Cancer Inform; 2017; 16():1176935117691267. PubMed ID: 28469388
[No Abstract] [Full Text] [Related]
14. Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes.
Rhee JK; Kim TM
BMC Med Genomics; 2018 Apr; 11(Suppl 2):29. PubMed ID: 29697365
[TBL] [Abstract][Full Text] [Related]
15. A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma.
Li XC; Wang MY; Yang M; Dai HJ; Zhang BF; Wang W; Chu XL; Wang X; Zheng H; Niu RF; Zhang W; Chen KX
Ann Oncol; 2018 Apr; 29(4):938-944. PubMed ID: 29351612
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genomic characterization of mutational signatures across human cancers.
Liao J; Bai J; Pan T; Zou H; Gao Y; Guo J; Xu Q; Xu J; Li Y; Li X
Int J Cancer; 2023 Apr; 152(8):1613-1629. PubMed ID: 36533638
[TBL] [Abstract][Full Text] [Related]
17. Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals
McClure MB; Kogure Y; Ansari-Pour N; Saito Y; Chao HH; Shepherd J; Tabata M; Olopade OI; Wedge DC; Hoadley KA; Perou CM; Kataoka K
Cancer Res Commun; 2023 Feb; 3(2):281-296. PubMed ID: 36860655
[TBL] [Abstract][Full Text] [Related]
18. [Mutations of tumor suppressor gemne TP53 in tobacco smoke-associated tumors].
Szyfter K; Kiwerska K; Rydzanicz M; Kruszyna Ł; Zemleduch T; Jagodziński P
Przegl Lek; 2009; 66(10):603-7. PubMed ID: 20301891
[TBL] [Abstract][Full Text] [Related]
19. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer.
Zhang F; Zhong W; Li H; Huang K; Yu M; Liu Y
Front Cell Dev Biol; 2021; 9():665265. PubMed ID: 34124046
[TBL] [Abstract][Full Text] [Related]
20. Mutation Signatures Including APOBEC in Cancer Cell Lines.
Jarvis MC; Ebrahimi D; Temiz NA; Harris RS
JNCI Cancer Spectr; 2018 Jan; 2(1):. PubMed ID: 29888758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
